ArticleBMC cancer2008
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.
Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
198 citing papers in PubMed, 1 synthesis or guideline pooled it, 392 citations in OpenAlex.
- Association between miR34b/c polymorphism rs4938723 and cancer risk: a meta-analysis of 11 studies including 6169 cases and 6337 controls.Medical science monitor : international medical journal of experimental and clinical research · 2014Pooled it
- miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma.Molecular therapy. Nucleic acids · 2026Article
- The intersection of ferroptosis and non-coding RNAs: a novel approach to lung cancer.Irish journal of medical science · 2025Review
- MALAT1 Expression Is Deregulated in miR-34a Knockout Cell Lines.Non-coding RNA · 2025Article
- Carvedilol sensitizes paclitaxel-resistant gastric cancer AGS cells to paclitaxel: influences on apoptotic regulators, Notch, PI3K/AKT, ERK1/2 signaling pathways, and miR-34a expression.Medical oncology (Northwood, London, England) · 2025Article
- Role of noncoding RNA as a pacemaker in cancer stem cell regulation: a review article.Journal of the Egyptian National Cancer Institute · 2025Review
- Evidence for a TMAO-HULC-miRNA regulatory axis in colorectal cancer cells.International journal of molecular and cellular medicine · 2025Article
- Review
- miRNAs in HCC, pathogenesis, and targets.Hepatology (Baltimore, Md.) · 2024Article
- The Role of MicroRNA-124-3p in Breast Cancer Stem Cell Inhibition by Benzyl Isothiocyanate.Pharmaceutical research · 2024Article
- Article
- The role of microRNAs in the gastric cancer tumor microenvironment.Molecular cancer · 2024Review
- Multifunctional elastin-like polypeptide nanocarriers for efficient miRNA delivery in cancer therapy.Journal of nanobiotechnology · 2024Article
- MicroRNA-34 and gastrointestinal cancers: a player with big functions.Cancer cell international · 2024Review
- MicroRNA-34a-5p: A pivotal therapeutic target in gallbladder cancer.Molecular therapy. Oncology · 2024Article
- Multifaceted role of microRNAs in gastric cancer stem cells: Mechanisms and potential biomarkers.World journal of gastrointestinal oncology · 2024Review
- Vil-Cre specific Slfn3KO mice exhibit sex-specific differences in lung, stomach, cecum, kidney, and proximal colon differentiation markers and Slfn family members expression levels.Biochemistry and biophysics reports · 2023Article
- Mechanism of cisplatin resistance in gastric cancer and associated microRNAs.Cancer chemotherapy and pharmacology · 2023Review
- Review
- miRNA: A Promising Therapeutic Target in Cancer.International journal of molecular sciences · 2022Review
138 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundMicroRNAs (miRNAs), some of which function as oncogenes or tumor suppressor genes, are involved in carcinogenesis via regulating cell proliferation and/or cell death. MicroRNA miR-34 was recently found to be a direct target of p53, functioning downstream of the p53 pathway as a tumor suppressor. miR-34 targets Notch, HMGA2, and Bcl-2, genes involved in the self-renewal and survival of cancer stem cells. The role of miR-34 in gastric cancer has not been reported previously. In this study, we examined the effects of miR-34 restoration on p53-mutant human gastric cancer cells and potential target gene expression.
methodsHuman gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system, and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter. Potential target gene expression was assessed by Western blot for proteins, and by quantitative real-time RT-PCR for mRNAs. The effects of miR-34 restoration were assessed by cell growth assay, cell cycle analysis, caspase-3 activation, and cytotoxicity assay, as well as by tumorsphere formation and growth.
resultsHuman gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2, Notch, and HMGA2. Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34. Restoration of miR-34 chemosensitized Kato III cells with a high level of Bcl-2, but not MKN-45 cells with a low level of Bcl-2. miR-34 impaired cell growth, accumulated the cells in G1 phase, increased caspase-3 activation, and, more significantly, inhibited tumorsphere formation and growth.
conclusionOur results demonstrate that in p53-deficient human gastric cancer cells, restoration of functional miR-34 inhibits cell growth and induces chemosensitization and apoptosis, indicating that miR-34 may restore p53 function. Restoration of miR-34 inhibits tumorsphere formation and growth, which is reported to be correlated to the self-renewal of cancer stem cells. The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2, Notch, and HMGA2, indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making. Our study suggests that restoration of the tumor suppressor miR-34 may provide a novel molecular therapy for p53-mutant gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.